U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H8NO2.Na
Molecular Weight 125.1016
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM GAMMA-AMINOBUTYRATE

SMILES

[Na+].NCCCC([O-])=O

InChI

InChIKey=MJGIKHNOXNRIHX-UHFFFAOYSA-M
InChI=1S/C4H9NO2.Na/c5-3-1-2-4(6)7;/h1-3,5H2,(H,6,7);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C4H8NO2
Molecular Weight 102.1118
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

γ-aminobutyric acid (GABA), a naturally occurring substance, which is a product of decarboxylation of the amino acid glutamate mediated by the synthesizing enzyme glutamic acid decarboxylase. GABA is a major inhibitory neurotransmitter of the brain and acts mainly through the GABAA receptor (GABAAR). GABA is locally produced by the pancreatic beta cells. GABAARs are also expressed in various immune cells, including T-cells, peripheral blood mononuclear cells, and are known to exert immune-inhibitory effects. Recently was studied, that GABA has the potential in treatment of Type I Diabetes. Moreover, was shown, that GABA administration could enhance immunity under stress conditions.

Originator

Curator's Comment: -Aminobutyric acid (GABA) was initially identified as a major inhibitory neurotransmitter in the brain by Roberts and Frankel in 1950

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
200.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
THERAPENTIN-90

Approved Use

Gabapentin Capsules is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin Capsules is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.

Launch Date

1.31224319E12
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
PubMed

PubMed

TitleDatePubMed
gamma-Aminobutyric acid in brain: its formation from glutamic acid.
1950 Nov
Patents

Patents

Sample Use Guides

Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.
Route of Administration: Oral
The HEK293 cells constitutively expressing exogenous GABA receptor π subunit (GABRP) revealed the growth-promoting effect of GABA treatment (serial concentrations: 0, 1, 10, 100 μmol/L);for 6 d). GABA treatment stimulated GABRP-positive pancreatic ductal adenocarcinoma (PDAC) cell proliferatio and activated the mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/Erk) cascade. These findings imply that GABA and GABRP could play important roles in PDAC development and progression, and that this pathway can be a promising molecular target for the development of new therapeutic strategies for PDAC.
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:42:47 UTC 2023
Edited
by admin
on Thu Jul 06 02:42:47 UTC 2023
Record UNII
Y800S030EF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM GAMMA-AMINOBUTYRATE
Systematic Name English
BUTANOIC ACID, 4-AMINO-, SODIUM SALT (1:1)
Systematic Name English
SODIUM 4-AMINOBUTANOATE
Systematic Name English
SODIUM .GAMMA.-AMINOBUTYRATE
Systematic Name English
SODIUM 4-AMINOBUTYRATE
Systematic Name English
4-AMINOBUTYRIC ACID SODIUM SALT
Systematic Name English
BUTANOIC ACID, 4-AMINO-, MONOSODIUM SALT
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID90216299
Created by admin on Thu Jul 06 02:42:47 UTC 2023 , Edited by admin on Thu Jul 06 02:42:47 UTC 2023
PRIMARY
CAS
6610-05-5
Created by admin on Thu Jul 06 02:42:47 UTC 2023 , Edited by admin on Thu Jul 06 02:42:47 UTC 2023
PRIMARY
FDA UNII
Y800S030EF
Created by admin on Thu Jul 06 02:42:47 UTC 2023 , Edited by admin on Thu Jul 06 02:42:47 UTC 2023
PRIMARY
PUBCHEM
23663645
Created by admin on Thu Jul 06 02:42:47 UTC 2023 , Edited by admin on Thu Jul 06 02:42:47 UTC 2023
PRIMARY
ECHA (EC/EINECS)
229-561-1
Created by admin on Thu Jul 06 02:42:47 UTC 2023 , Edited by admin on Thu Jul 06 02:42:47 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE